Ad.IL-12 was administered in doses ranging from 2.5 × 10 10 to 3 × 10 12 viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients ...
ST. LOUIS--(BUSINESS WIRE)--Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results ...
Research article published in Pancreas Journal reports initial safety and clinical outcome data from a Phase 2a clinical trial of IT LSAM-PTX in LAPC. Two posters presented at AACR Special Conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback